Delivery Order SPE2DR25D9168-SPE2DR26FCRS7
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,493.75 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Fasenra Pen 30 mg/mL. The award, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, utilizes firm fixed-price pricing with no set-aside designation, indicating the vendor competed in unrestricted federal procurement. DMS Pharmaceutical Group...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $4,887.00, is for the supply of FASENRA PEN 30 MG/MLML, a pharmaceutical product. This delivery order is under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group that has a ceiling value of up to $499,999,999 and runs through December 31, 2025. The IDC allows DLA to...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $14,661.00 to DMS Pharmaceutical Group Inc., a woman-owned small business (WOSB) pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of FASENRA 30 MG/ML SYRINGEML, a specialty pharmaceutical product, with a performance period running through September 5, 2024. This delivery order contract is part of a larger $499,999,999 indefinite delivery contract (IDC) that...
- The Defense Logistics Agency (DLA) awarded a $39,900 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/mL syringes. The award, issued on December 17, 2025, with a completion date of December 18, 2025, represents a firm fixed-price delivery order with no set-aside designation. This contract leverages DMS Pharmaceutical Group's position as a regional prime vendor under the DLA's Pharmaceutical...
- This firm fixed-price delivery order worth $2,443.50 was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The order is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialty medication, with a completion date of September 9, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows...
- The Defense Logistics Agency (DLA) awarded a $14,962.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Fasenra 30 mg/ml syringes. The award, issued on December 2, 2025, with an ultimate completion date of December 3, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was selected as...
- The Defense Logistics Agency awarded a $2,275.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for FASENRA Pen 30 mg/ml. The delivery order, which became effective on September 5, 2025, with an ultimate completion date of September 26, 2025, will be performed in Conshohocken, Pennsylvania. This award was made without a set-aside designation, allowing the contractor to compete directly in the...
- The Defense Logistics Agency awarded a $24,937.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Fasenra 30 mg/mL syringes. The delivery order, issued on November 24, 2025, with an ultimate completion date of November 25, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This award falls under...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $24,435 to DMS Pharmaceutical Group Inc. for Fasenra 30 mg/ml syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order is scheduled for completion by November 3, 2025, and represents one of numerous...
- The U.S. Defense Logistics Agency (DLA) awarded a $4,887.00 firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of FASENRA 30 MG/ML SYRINGEML, a specialized pharmaceutical product, with a period of performance through November 8, 2024. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc. with the DLA under the...
- SPE2DR25D9168Indefinite Delivery Contract
- SPE2DR25D9168-SPE2DR26FCRS7Delivery Order
The Defense Logistics Agency issued a delivery order valued at $14,962.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of FASENRA PEN 30 MG/ML. This firm fixed-price delivery order, awarded on January 5, 2026, with an ultimate completion date of January 6, 2026, was issued without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring pharmaceutical supply needs across Department of Defense healthcare facilities worldwide. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, leveraging its small business status and comprehensive product portfolio spanning branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's performance on this delivery order aligns with its broader role under the PPV-G GEN V contract, which carries a ceiling value of $499,999,999 through December 31, 2036, and positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting military healthcare operations globally. With no identified subcontractors and all funding provided by the Defense Logistics Agency, this award reflects the contractor's consistent performance across the federal pharmaceutical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 1/4/26 |